A gut bacterial compound from pomegranates, walnuts and berries, sold purified because most people make little from food. Muscle endurance and markers of energy handling and inflammation improve most repeatably; strength is less consistent; trained athletes gain recovery, not performance. Brain, joint and cancer claims rest on animal and cell work. Safety over months looks unremarkable; product quality is unreliable. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | <0.5 mg/L | Tracks the inflammation most consistently lowered |
| IL-6 | <1.5 pg/mL | A second inflammation signal complementing hs-CRP |
| ALT and AST | ALT 10–19 U/L (women), 10–26 U/L (men); AST 10–26 U/L | Confirms normal liver handling of the compound |
| eGFR with serum creatinine | >90 mL/min/1.73 m² | Conjugated urolithin A is cleared by the kidneys |
| Fasting insulin | 2–5 µIU/mL | Sets the metabolic context for judging the effect |
| HbA1c | 4.8–5.3% | A slower metabolic anchor, unaffected by one day |
| Lipid panel with ApoB | ApoB <80 mg/dL; HDL-C >50 mg/dL (women), >45 mg/dL (men) | The only cardiovascular signal was a lipid shift |
| Creatine kinase | 40–200 U/L | Recovery marker, most useful when training hard |
| Plasma urolithin A glucuronide | Detectable, ideally >1 µmol/L at 6 hours post-dose | Direct proof of product content and absorption |
Cadence: Full panel at baseline, 3 and 6 months, then every 6–12 months; functional tests at baseline, 2 and 4 months